European surveillance of antimicrobial resistance in Neisseria gonorrhoeae
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsCole, Michelle J
Chisholm, Stephanie A
Lowndes, Catherine M
Ison, Catherine A
MetadataShow full item record
CitationSex Transm Infect. 2010, 86(6):427-32
AbstractOBJECTIVE: To perform a European sentinel surveillance study for antimicrobial resistance (AMR) in Neisseria gonorrhoeae as part of the European Surveillance of Sexually Transmitted Infections Programme. METHODS: From 2006 to 2008 17 countries participated in the AMR surveillance programme. The susceptibility of a total of 3528 consecutive isolates was tested using the agar dilution breakpoint technique or Etests for ciprofloxacin, penicillin, tetracycline, azithromycin, spectinomycin and ceftriaxone. Nitrocefin was used to detect β-lactamase activity. RESULTS: Rates of resistance to ciprofloxacin, the previously recommended treatment, were high across Europe (42-52%), indicating that usage is no longer appropriate. Although resistance to the currently recommended treatment, ceftriaxone, was not demonstrated, a concerning upward drift in the minimal inhibitory concentration (MIC) distribution was identified since an earlier European study in 2004. No resistance to spectinomycin was seen, whereas azithromycin resistance varied from 2% to 7% and isolates from Scotland (n=4) and Ireland (n=1) showed high-level resistance (MIC >256 mg/l). High-level resistance to tetracycline and penicillin remained relatively constant at 16% and 12%, respectively. CONCLUSIONS: AMR is an ongoing problem in Europe, with high rates of resistance to many previously recommended therapeutic agents observed in many European countries. Continual European and global surveillance of AMR in N gonorrhoeae is essential to monitor for increasing, emerging and high-level resistance to therapeutically relevant agents and to inform treatment guidelines so optimum treatments are administered.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe.
- Authors: Martin IM, Hoffmann S, Ison CA, ESSTI Network.
- Issue date: 2006 Sep
- Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial.
- Authors: Unemo M, Shipitsyna E, Domeika M, Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group.
- Issue date: 2010 Nov
- The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008.
- Authors: Kubanova A, Frigo N, Kubanov A, Sidorenko S, Lesnaya I, Polevshikova S, Solomka V, Bukanov N, Domeika M, Unemo M
- Issue date: 2010 Apr 8
- [The monitoring of Neisseria gonorrhoeae infection incidence and its resistance in Suceava County].
- Authors: Filipiuc S, Nicolae O, Luncă C, Iancu LS
- Issue date: 2009 Oct-Dec
- Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone.
- Authors: Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, Van de Laar MJ
- Issue date: 2013 Jan 17